International Journal of Clinical and Experimental Neurology
ISSN (Print): 2379-7789 ISSN (Online): 2379-7797 Website: Editor-in-chief: Zhiyou Cai, MD
Open Access
Journal Browser
International Journal of Clinical and Experimental Neurology. 2019, 7(1), 7-11
DOI: 10.12691/ijcen-7-1-2
Open AccessArticle

The Association between Adenosine Triphosphate Binding Cassette B1 Cytosine 3435 Thymine Polymorphism and Pharmacoresistant Idiopathic Epilepsy: An Egyptian Study

Yosria A. Altaweel1, Amr E. Kamel1, Karam S. Amin1, Somia H. Abd-ALLAH2 and Shaimaa A. Elaidy1,

1Neurology Department, Zagazig University, Egypt

2Medical biochemistry Department, Zagazig University, Egypt

Pub. Date: May 20, 2019

Cite this paper:
Yosria A. Altaweel, Amr E. Kamel, Karam S. Amin, Somia H. Abd-ALLAH and Shaimaa A. Elaidy. The Association between Adenosine Triphosphate Binding Cassette B1 Cytosine 3435 Thymine Polymorphism and Pharmacoresistant Idiopathic Epilepsy: An Egyptian Study. International Journal of Clinical and Experimental Neurology. 2019; 7(1):7-11. doi: 10.12691/ijcen-7-1-2


Background: P-glycoprotein (P-gp) is a drug efflux transporter present in the blood brain barrier whose function was suggested to be modified by a genetic polymorphism affecting ABCB1 C3435T gene at exon 26. Overexpression was related to homozygous C allele in some studies, however other studies in different ethnic populations showed relation to homozygous T allele, furthermore others failed to confirm any relation to resistance to therapeutic effects of AEDs. Aim of the study: Our aim is to find out the association between C3435T polymorphism and pharmacoresistance in idiopathic epilepsy in order to identify early the pharmacoresistant patients so we can select the proper AED and other proper therapeutic modalities. Patients and methods: Our case-control study was conducted on 44 idiopathic epileptic patients (22 drug-resistant and 22 drug-responsive epilepsy) and 44 healthy controls of comparable age and sex. Blood samples were obtained. Allele and genotype frequencies were evaluated between our study groups and their association with pharmacoresistance, some historical and semiology of epilepsy. Results: Our work revealed a lower risk of drug resistance in patients with the genotype CT (OR: 0.8) in comparison to genotypes CC and TT (OR: 1.2, 1 respectively) but the results were not statistically significant. However, significant association regarding daytime seizures was found with genotype CC in comparison to genotypes CT and TT. Conclusion: Daytime seizures were found to be more prevalent among those with CC genotype and this association was significant. The risk of drug resistant epilepsy was lower in patients with CT than those with CC and TT genotypes, but this association was not statistically significant in our study.

idiopathic epilepsy drug resistant epilepsy polymorphism ABCB1

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Jessica, J.F., Ingrid, E.S., Robert, S.F, “The new definition and classification of seizures and epilepsy,” Epilepsy Research, 139. 73-79. 2018.
[2]  Panayiotopoulos, C.P, Syndromes of idiopathic generalized epilepsies not recognized by the International League against Epilepsy. Epilepsia, 2005, 46. 57-66.
[3]  Schmidt, D. and Loscher, W, “Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms,” Epilepsia, 46 (6). 858-877. 2005.
[4]  Boonluksiri, P., Visuthibhan, A. and Katanyuwong, K, “Clinical Prediction Rule of Drug Resistant Epilepsy in Children,” Journal of epilepsy research, 5(2). 84-88. 2015.
[5]  Siddiqui, A., Kerb, R., Weale, ME., Brinkmann, U., Smith, A., Goldstein, D.B., Wood, N.W. and Sisodiya, S.M, “Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1,” New England Journal of Medicine, 348(15). 1442-1448. 2003.
[6]  Manna, J. and Sanjeev, T, “Role of multidrug transporters in neurotheraputics,” Annals of Indian Academy of Neurology, 12(2). 89-98. 2009.
[7]  Komar, A.A, “Silent SNPs: impact on gene function and phenotype,” Pharmacogenomics, 8(8). 1075-1080. 2007.
[8]  Kwan, P., Arzimanoglou, A., Berg, A., Brodie, M., Hauser, W., Mathern, G., Perucca, S., Wiebe, S. and French, J, “Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies,” Epilepsia, 51(6).1069-1077. 2010.
[9]  Morisky, D.E., Green, L.W. and Levine, D.M, “Concurrent and predictive validity of a self-reported measure of medication adherence,” Medical Care, 24. 67-74. 1986.
[10]  Emich-Widera, E., Likus, W., Kazek, B., Sieroń, A. and Urbanek, K, “Polymorphism of ABCB1/MDR1 C3435T in Children and Adolescents with Partial Epilepsy is due to Different Criteria for Drug Resistance – Preliminary Results,” Medical Science Monitor, 20. 1654-1661. 2014.
[11]  Zimprich, F., Sunder-Plassmann R., Stogmann, E., Gleiss, A., Dal-Bianco , A., Zimprich, A., Plumer, S., Baumgartner, C. and Mannhalter, C, “Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy,” Neurology, 63.1087-1089. 2004.
[12]  Hung, C.C., Tai, J.J., Lin, C.J., Lee, M.J. and Liou, H.H, “Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response,” Pharmacogenomics, 6. 411-417. 2005.
[13]  Ebid, A.H., Ahmed, M.M. and Mohammed, S.A,”Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study,” Therapeutic Drug Monitoring, 29(3). 305-312. 2007.
[14]  Dericioglu, N., Babaoglu, M.O., Yasar, U., Bal, I.B., Bozkurt, A. and Saygi, S, “Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene,” Epilepsy Research, 80. 42-46. 2008.
[15]  Ozgon, G.O., Bebek, N., Gul, G. and Cine, N, “Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey,” European Neurology, 59(1-2). 67-70. 2008.
[16]  Shahwana, A., Murphya, K., Dohertyc, C., Cavalleri, G., Muckiane, C., Dickere, P., McCarthya, M., Kinironsa, P., Goldsteind, D. and Delantya, N, “The controversial association of ABCB1 polymorphisms in refractory epilepsy: An analysis of multiple SNPs in an Irish population,” Epilepsy Research, 73. 192-198. 2007.
[17]  Kim, D.W., Kim, M., Lee, S.K., Kang, R. and Lee, S.Y, “Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy,” Seizure, 15. 344-347. 2006.
[18]  Seo, T., Ishitsu, T., Ueda, N., Nakada, N., Yurube, K., Ueda, K. and Nakagawa, K, “ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients,” Pharmacogenomics, 7(4). 551-561. 2006.
[19]  Ponnala, S., Chaudhari, J.R., Jaleel, M.A., Bhiladvala, D., Kaipa, P.R., Das, U.N. and Hasan, Q, “Role of MDR1 C3435T and GABRG2 C588T gene polymorphisms in seizure occurrence and MDR1 effect on antiepileptic drug (phenytoin) absorption,” Genetic Testing and Molecular Biomarkers, 16. 550-557. 2012.
[20]  Shaheen, U., Prasad, D.K., Sharma, V., Suryaprabha, T., Ahuja, Y.R., Jyothy, A. and Munshi, A, “Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy,” Epilepsy Research, 108(2). 251-256. 2013
[21]  Sayyah, M., Kamgarpour, F., Maleki, M., Karimipoor, M., Gharagozli, K. and Shamshiri, A.R, “Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients,” Epileptic Disorder, 13(2). 155-165. 2011.